BioNano Genomics (NASDAQ: BNGO) is up 35% in the last few days.
One of today’s trending stocks is BioNano Genomics, so we thought it would be helpful to list two of the best places to buy BioNano Genomics stock so you can get involved.
Where to buy BNGO stock today
If you wondering where to buy BNGO shares, the answer is a reliable stockbroker. These are popular platforms that allow retail investors to form their very own investment portfolio including stocks, cryptocurrencies, commodities and forex.
Our team of analysts believe the two options below provide the best combination of low fees, a strong interface and powerful tools. They are two of the best platforms to buy BioNano Genomics shares:
eToro is one of the world's leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It's social copy trading features make it a great choice for those getting started.
Financial company driven by technology and offering all-in-one self-directed investment platform that provides excellent user experience.
What is BioNano Genomics?
Founded in 2003 and headquartered in San Diego, California, the company is a science and technology player at the forefront of genetic disease research, cancer research, and cytogenomics with genome imaging.
It provides a platform to analyse the long segments of genomic DNA and general biomolecules structural variations.
BNGO’s range of products includes software, automated imaging instruments, proprietary nanochannel chips and reagents.
Why is BioNano Genomics on the rise?
There are two main reasons. First, is BioNano’s appointment of a new COO, industry veteran Jason Priar. He brings a wealth of experience working with labs that perform genome analysis in both cancer and genetic diseases.
However, the primary reason appears to be the interest generated by the Reddit forum, WallStreetBets. Quite how sustainable this proves to be remains to be seen.
Should I buy BNGO stock?
If you believe in the company’s technical prowess and leadership, and you think it can be at the forefront of disease management, curation and prevention in the foreseeable future, it is worth investigating the investment proposition further.
However, while revenue is on the up, the company’s losses have widened, and this is to be expected for a speculative and early-stage tech player. Just make sure you are aware of the risks and have conducted the necessary due diligence before investing.
BNGO price prediction
The consensus of reputable analysts given a BioNano Genomics price target of $14 at the high end and $12 as the median for the next 12 months. This is hardly the most exciting projection, though this company is likely to be a slow burn growth opportunity, and rewards could come much further down the line as the company achieves commercialisation.